Results 41 to 50 of about 1,341 (183)

A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin

Journal of Fungi
This mini-review summarizes the clinical outcomes and antifungal susceptibility results, where available, for three new antifungals, including fosmanogepix, ibrexafungerp, and rezafungin, against Candida isolates cultured from patients in clinical trials.
Ana Espinel-Ingroff, Nathan P. Wiederhold   +1 more
doaj   +2 more sources

Clinical Significance of Drug–Drug Interaction Studies During Therapeutic Peptide Drug Development: Follow‐Up Investigation of Therapeutic Peptides Approved Between 2021 and 2024 [PDF]

Clin Transl Sci
ABSTRACT The risk of clinically relevant drug–drug interactions (DDIs) for therapeutic peptides remains unclear, mandating a comprehensive analysis for this modality. In our prior study, we analyzed DDIs for 31 peptide drugs approved between January 2008 and August 2021.
Säll C, Argikar U, Hilgendorf C, Schiller H, Sonesson A, Umehara K, Wang K.   +6 more
europepmc   +2 more sources

Tn-seq screens in Candida glabrata treated with echinocandins and ibrexafungerp reveal pathways of antifungal resistance and cross-resistance [PDF]

mSphere
Candida glabrata (also known as Nakaseomyces glabratus) is the second most common cause of candidiasis, next to Candida albicans, and is rising in prevalence due to intrinsic and acquired mechanisms of antifungal resistance.
Timothy J. Nickels, Kyle W. Cunningham
doaj   +2 more sources

Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 44, Issue 6, Page 435-443, June 2024.
Rezafungin is a second‐generation, once‐weekly echinocandin antifungal approved for the treatment of invasive candidiasis, including candidemia. In phase II/III studies of rezafungin versus caspofungin, patients with severe hepatic impairment were ...
Shawn Flanagan, V. Ong, T. Marbury, A. Jandourek, R. Gandhi, T. Sandison   +5 more
semanticscholar   +2 more sources

Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials. [PDF]

Crit Care
Invasive candidiasis/candidemia (IC/C) is associated with a substantial health economic burden driven primarily by prolonged hospital stay. The once-weekly IV echinocandin, rezafungin acetate, has demonstrated non-inferiority to caspofungin in the ...
Honoré PM, Bassetti M, Cornely OA, Dupont H, Fortún J, Kollef MH, Pappas P, Pullman J, Vazquez J, Bielicka I, Dickerson S, Manamley N, Sandison T, Thompson GR.   +13 more
europepmc   +2 more sources

P-1095. Activity of Rezafungin against Clinical Isolates of Uncommon Species of Candida spp [PDF]

Open Forum Infect Dis
Background Rezafungin (RZF) is a long-acting echinocandin recently approved by the FDA to treat invasive candidiasis (IC) and candidemia. RZF CLSI breakpoints are available for Candida albicans, C. auris (CARS), C. dubliniensis (CDUB), C.
Marisa L Winkler, P. Rhomberg, Abby L. Klauer, M. Castanheira   +3 more
europepmc   +2 more sources

High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies [PDF]

Microorganisms
Invasive fungal diseases (IFDs) still represent a relevant cause of mortality in patients affected by hematological malignancies, especially acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) undergoing remission induction chemotherapy, and
Giovanni Mori, Sara Diotallevi, Francesca Farina, Riccardo Lolatto, Laura Galli, Matteo Chiurlo, Andrea Acerbis, Elisabetta Xue, Daniela Clerici, Sara Mastaglio, Maria Teresa Lupo Stanghellini, Marco Ripa, Consuelo Corti, Jacopo Peccatori, Massimo Puoti, Massimo Bernardi, Antonella Castagna, Fabio Ciceri, Raffaella Greco, Chiara Oltolini   +19 more
doaj   +3 more sources

Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin [PDF]

, 2023
Introduction: Invasive Candida Infections (ICIs) have undergone a series of significant epidemiological, pathophysiological, and clinical changes during the last decades, with a shift toward non-albicans species, an increase in the rate of exogenous ...
De Rosa, Francesco Giuseppe, Mikulska, Malgorzata, Oliva, Alessandra, Pea, Federico, Sanguinetti, Maurizio, Tascini, Carlo, Venditti, Mario   +6 more
core   +8 more sources

Efficacy of Rezafungin on Candida albicans Endophthalmitis in a Rabbit Model

Pathogens and Immunity
Background: Endophthalmitis, a severe infection of the intraocular tissues that can result in permanent loss of vision if not immediately treated, is often caused by fungi, namely Candida albicans.
John Saghir, Janet Herrada, Lisa Long, Erin San Valentin, Thomas S. McCormick, Mahmoud A. Ghannoum   +5 more
doaj   +2 more sources

The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models

Journal of Fungi, 2021
Rezafungin is a novel echinocandin in Phase 3 development for prevention of invasive fungal disease caused by Candida spp., Aspergillus spp. and Pneumocystis jirovecii in blood and marrow transplantation patients.
Melanie T. Cushion, Alan Ashbaugh
doaj   +1 more source